UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000037738
Receipt number R000043035
Scientific Title Efficacy trial of single intake of plant derived ingredient. [g2019004]
Date of disclosure of the study information 2019/08/20
Last modified on 2022/04/13 14:32:30

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Efficacy trial of single intake of plant derived ingredient. [g2019004]

Acronym

Efficacy of plant derived ingredient [g2019004]

Scientific Title

Efficacy trial of single intake of plant derived ingredient. [g2019004]

Scientific Title:Acronym

Efficacy of plant derived ingredient [g2019004]

Region

Japan


Condition

Condition

Healthy adults

Classification by specialty

Not applicable Adult

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To investigate effects of a plant derived ingredient on gastrointestinal hormone in healthy male adults

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Postprandial GLP-1 concentration (baseline, 30, 60, 90, 105, and 120 minutes after ingestion of a test meal)

Key secondary outcomes

Postprandial concentration of glucose, insulin and GIP (baseline, 30, 60, 90, 105, and 120 minutes after ingestion of a test meal)


Base

Study type

Interventional


Study design

Basic design

Cross-over

Randomization

Randomized

Randomization unit

Individual

Blinding

Double blind -all involved are blinded

Control

Placebo

Stratification

YES

Dynamic allocation

NO

Institution consideration


Blocking

YES

Concealment

No need to know


Intervention

No. of arms

6

Purpose of intervention

Treatment

Type of intervention

Food

Interventions/Control_1

Single consumption of control food > wash out (1 week) > Single consumption of test food A consumption > wash out (1 week) > Single consumption of test food B consumption

Interventions/Control_2

Single consumption of control food > wash out (1 week) > Single consumption of test food B consumption > wash out (1 week) > Single consumption of test food A consumption

Interventions/Control_3

Single consumption of test food A consumption > wash out (1 week) > Single consumption of test food B consumption > wash out (1 week) > Single consumption of Control food consumption

Interventions/Control_4

Single consumption of test food A consumption > wash out (1 week) > Single consumption of Control food consumption > wash out (1 week) > Single consumption of test food B consumption

Interventions/Control_5

Single consumption of test food B consumption > wash out (1 week) > Single consumption of test food A consumption > wash out (1 week) > Single consumption of Control food consumption

Interventions/Control_6

Single consumption of test food B consumption > wash out (1 week) > Single consumption of Control food consumption > wash out (1 week) > Single consumption of test food A consumption

Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

30 years-old <=

Age-upper limit

65 years-old >

Gender

Male

Key inclusion criteria

(1) Adult aged from 30 y to 65 y
(2) Fasting glucose from 95 to 125 mg/dL

Key exclusion criteria

(1) Diabetes mellitus
(2) Taking medicine related diabetes mellitus
(3) BMI<=30kg/m2
(4) Having history or presence of cardiovascular disease or cerebrovascular disease
(5) Presence of liver, kidney or respiratory disease, endocrine disorder, metabolic disorder, organ disorder, gout, rheumatism, autoimmune disease, allergy disease, mental disorder, cancer, infection disease, or other diseases
(6) Having history of resection of gastrointestinal tract
(7) Thyroid deficiency
(8) Heavy alcohol drinker (over 30g per day)
(9) Donated over 200 mL of blood within the last one month prior to the study or over 400 mL of blood within the last three months prior to the study
(10) Severe anemia (Hb <=7g/dL)
(11) Food allergies for test foods
(12) Planned to participate in other clinical study during current study
(13) Shift worker
(14) Determined to be unqualified by the physician in charge or the responsible person of the study

Target sample size

18


Research contact person

Name of lead principal investigator

1st name Shinichiro
Middle name
Last name Saito

Organization

Kao Corporation

Division name

Biological Science Research laboratories

Zip code

131-8501

Address

2-1-3, Bunka, Sumida-ku, Tokyo, 131-8501, Japan

TEL

03-5630-7456

Email

saito.shinichiro@kao.com


Public contact

Name of contact person

1st name Aya
Middle name
Last name Yanagimoto

Organization

Kao Corporation

Division name

Biological Science Research laboratories

Zip code

131-8501

Address

2-1-3, Bunka, Sumida-ku, Tokyo, 131-8501, Japan

TEL

03-5630-7476

Homepage URL


Email

yanagimoto.aya@kao.com


Sponsor or person

Institute

Kao Corporation

Institute

Department

Personal name



Funding Source

Organization

Kao Corporation

Organization

Division

Category of Funding Organization

Profit organization

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Ueno-Asagao Clinic Ethical Review Committee

Address

Kairaku Building 6F, 2-7-5, Higashiueno, Taito-ku, Tokyo, 110-0015, Japan

Tel

03-6240-1162

Email

jimukyoku@tes-h.co.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2019 Year 08 Month 20 Day


Related information

URL releasing protocol

Unpublished due to the protocol including the intellectual property rights

Publication of results

Published


Result

URL related to results and publications

works in progress

Number of participants that the trial has enrolled

18

Results

A significant difference was observed in the primary outcome.

Results date posted

2022 Year 04 Month 13 Day

Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics

Healthy adults

Participant flow

16 participants completed and 18 subjects were incorporated into the analyses (2 participant declined due to personal reasons)

Adverse events

none

Outcome measures

gastrointestinal hormone

Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Main results already published

Date of protocol fixation

2019 Year 07 Month 31 Day

Date of IRB

2019 Year 08 Month 07 Day

Anticipated trial start date

2019 Year 09 Month 07 Day

Last follow-up date

2019 Year 10 Month 10 Day

Date of closure to data entry

2019 Year 10 Month 31 Day

Date trial data considered complete

2019 Year 12 Month 01 Day

Date analysis concluded

2020 Year 02 Month 28 Day


Other

Other related information



Management information

Registered date

2019 Year 08 Month 20 Day

Last modified on

2022 Year 04 Month 13 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000043035


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name